NASDAQ:CALA - Calithera Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.36 +0.14 (+2.68 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$5.36
Today's Range$5.12 - $5.37
52-Week Range$3.55 - $9.35
Volume171,632 shs
Average Volume145,117 shs
Market Capitalization$204.36 million
P/E Ratio-6.38
Dividend YieldN/A
Beta2.21
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25.95 million
Book Value$4.24 per share

Profitability

Net Income$-27,820,000.00

Miscellaneous

Employees73
Market Cap$204.36 million
OptionableOptionable

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) posted its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.52) EPS for the quarter, missing the Zacks' consensus estimate of ($0.40) by $0.12. Calithera Biosciences had a negative net margin of 90.65% and a negative return on equity of 31.73%. View Calithera Biosciences' Earnings History.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Calithera Biosciences.

What price target have analysts set for CALA?

2 analysts have issued 1 year target prices for Calithera Biosciences' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate Calithera Biosciences' share price to reach $14.00 in the next year. This suggests a possible upside of 161.2% from the stock's current price. View Analyst Price Targets for Calithera Biosciences.

What is the consensus analysts' recommendation for Calithera Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

Media coverage about CALA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Calithera Biosciences earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future.

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
  • Dr. Keith Orford, Chief Medical Officer (Age 47)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.00%), Dimensional Fund Advisors LP (3.26%), Northern Trust Corp (0.92%), Geode Capital Management LLC (0.91%), Bank of New York Mellon Corp (0.33%) and Bank of America Corp DE (0.24%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp, LL, Curtis Hecht and Keith Orford. View Institutional Ownership Trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Hikari Power Ltd, Bank of New York Mellon Corp, Acadian Asset Management LLC, Two Sigma Investments LP, New York State Common Retirement Fund, Barclays PLC and Northern Trust Corp. View Insider Buying and Selling for Calithera Biosciences.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Geode Capital Management LLC, Alps Advisors Inc., Paloma Partners Management Co, Two Sigma Advisers LP, Bank of America Corp DE, Rhumbline Advisers and Virtu Financial LLC. View Insider Buying and Selling for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $5.36.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $204.36 million and generates $25.95 million in revenue each year. The biotechnology company earns $-27,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Calithera Biosciences employs 73 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Featured Article: Preferred Stock

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel